 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Member Login |
Kineret® may be useful in the treatment of persons who, like yourself, have been diagnosed with the kind of diabetes we call Type 1 diabetes.
Why should I join the AIDA Study?
By becoming involved in our study, we will be able to closely study and determine the effect of Kineret on diabetes patients. Your contribution may help us come closer to finding treatments for people with diabetes all over the world.
 |
 |
|
|
How many times will I have to visit the Doctor/clinic?
|
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
